Amsterdam, the Netherlands, February 5, 2021 - LSP, one of Europe’s leading life sciences and healthcare investors, today announced the public offering of the shares of Pharvaris NV on Nasdaq. Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, is offering 8,270,500 of its ordinary shares at an initial public offering price of $20.00 per share, for total gross proceeds of approximately $165.4 million. In addition, Pharvaris has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,240,575 ordinary shares at the public offering price less underwriting discounts and commissions. The ordinary shares are expected to begin trading on the Nasdaq Global Select Market on February 5, 2021 under the symbol "PHVS." Pharvaris is a portfolio company of the LSP 5 fund.
Morgan Stanley, BofA Securities, and SVB Leerink are acting as joint book-running managers of the offering and Oppenheimer & Co. and Kempen & Co are acting as co-managers. A registration statement relating to this offering was declared effective by the Securities and Exchange Commission on February 4, 2021. The offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the offering may be obtained by contacting Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; BofA Securities, Inc., Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255; or, by email at qt.cebfcrpghf_erdhrfgf@obsn.pbz; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525 ext. 6105 or by email at flaqvpngr@fioyrrevax.pbz.
Martijn Kleijwegt, Managing Partner at LSP, commented, "We are proud to have been involved as founder investor of Pharvaris. Together with Kurma Partners and the founding team LSP embarked on a fantastic journey. Within 5 years the company transformed from a scientific project into a full fledged company being able to do an IPO on Nasdaq."
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
For more information please contact:
Martijn Kleijwegt, Managing Partner at LSP
+ 31 (0) 20 664 55 00
« back to overview